Medrogestone
Chemical compound / From Wikipedia, the free encyclopedia
Dear Wikiwand AI, let's keep it short by simply answering these key questions:
Can you list the top facts and stats about Medrogestone?
Summarize this article for a 10 year old
Medrogestone, sold under the brand name Colprone among others, is a progestin medication which has been used in menopausal hormone therapy and in the treatment of gynecological disorders.[6][2] It is available both alone and in combination with an estrogen.[7] It is taken by mouth.[2][8]
Clinical data | |
---|---|
Trade names | Colprone, others |
Other names | Metrogestone; Medrogesterone; AY-62022, NSC-123018, R-13615; 6,17α-Dimethyl-6-dehydroprogesterone; 6,17α-Dimethyl-4,6-pregnadiene-3,20-dione |
Pregnancy category |
|
Routes of administration | By mouth |
Drug class | Progestogen; Progestin |
ATC code | |
Legal status | |
Legal status |
|
Pharmacokinetic data | |
Bioavailability | Nearly 100%[1][2] |
Protein binding | 95%: Albumin (90%), CBGTooltip corticosteroid-binding globulin (3%), SHBGTooltip sex hormone-binding globulin (2%)[2] |
Metabolism | Hepatic (hydroxylation)[1] |
Elimination half-life | 35–36 hours[3][4][5] |
Identifiers | |
| |
CAS Number | |
PubChem CID | |
DrugBank | |
ChemSpider | |
UNII | |
KEGG | |
CompTox Dashboard (EPA) | |
ECHA InfoCard | 100.012.323 |
Chemical and physical data | |
Formula | C23H32O2 |
Molar mass | 340.507 g·mol−1 |
3D model (JSmol) | |
| |
|
Medrogestone is a progestin, or a synthetic progestogen, and hence is an agonist of the progesterone receptor, the biological target of progestogens like progesterone.[2] It has weak antiandrogenic, glucocorticoid, and antimineralocorticoid activity and no other important hormonal activity.[2][1][9][10] Due to its progestogenic activity, medrogestone has antigonadotropic effects.[1][2]
Medrogestone was described as early as 1963 and was introduced for medical use by at least 1966.[11][12][9] It has mostly been discontinued and remains available only in a few countries.[13][7]